LONG TERM USE OF CLOTRIMAZOLE AS A THERAPEUTIC AGENT FOR SICKLE CELL DISEASE

长期使用克霉唑作为镰状细胞病的治疗剂

• 批准号: 6120784
• 负责人: Carlo Brugnara
• 金额: $ 3.04万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6120784
• 关键词: antifungal agents; blood disorder chemotherapy; body water dehydration; cellular pathology; chemoprevention; clinical research; drug administration rate /duration; human subject; human therapy evaluation; imidazole; oral administration; potassium deficiency; sickle cell anemia; sickling inhibitor

Purpose is to study whether long term oral administration of the antimycotic drug Clotrimazole may prevent cell dehydration and sickling in patients with sickle cell anemia. Prevention of red cell K loss and dehydration is one of the possible therapeutic strategies for sickle cell anemia. Clotrimazole has been used in the past to treat fungal infection. The initial studies in patients with sickle cell disease have shown a reduction in the number of dense, sickled cells.

目的是研究是否长期口服给药 抗霉菌药物克霉唑可以防止细胞脱水和镰状化 镰状细胞性贫血的患者。预防红细胞K损失和 脱水是治疗镰状细胞瘤的可能策略之一 细胞性贫血克霉唑过去曾用于治疗真菌感染， 感染对镰状细胞病患者的初步研究 密集的镰状细胞数量减少。